海辰药业(300584.SZ)：注射用盐酸兰地洛尔被纳入国家医保目录

Core Insights - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security have announced the inclusion of Nanjing Haichen Pharmaceutical's injectable Landeolol hydrochloride (50mg) in the National Medical Insurance Directory for 2025, and the first-time inclusion of injectable Landeolol hydrochloride (150mg) [1] Group 1 - Landeolol hydrochloride is a new generation of rapid-acting, ultra-short-acting, highly selective β1 receptor blocker, with a selectivity ratio of approximately 255 times for β1 over β2 receptors, and 8 times more selective than another ultra-short-acting β blocker, Esmolol [2] - The drug has a rapid onset of action (1 to 6 minutes post-administration), a short half-life of about 4 minutes, and minimal negative impact on cardiac hemodynamics and respiratory function [2] - Landeolol is recommended for controlling ventricular rate in acute heart failure patients according to the 2023 National Heart Failure Guidelines, and is also a recommended drug for acute atrial fibrillation in the 2024 Chinese Emergency Management Guidelines [2] Group 2 - The product is projected to achieve sales revenue of 337.77 million yuan in 2024, accounting for 67.27% of the company's total revenue, making it the company's main product [2]